Opinion: A serious issue with the standardization of the adenovirus-based COVID-19 vaccines?

Szczegóły

Tytuł:: Opinion: A serious issue with the standardization of the adenovirus-based COVID-19 vaccines?
Autorzy:: Arand M; Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. .
Źródło:: Archives of toxicology [Arch Toxicol] 2021 Sep; Vol. 95 (9), pp. 3137-3139. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji:: Letter
Język:: English
Imprint Name(s):: Original Publication: Berlin, New York, Springer-Verlag.
MeSH Terms:: Adenoviridae/*genetics
COVID-19/*prevention & control
COVID-19 Vaccines/*standards
SARS-CoV-2/*immunology
Adenoviridae/immunology ; Animals ; Genetic Vectors ; HEK293 Cells ; Humans ; Mice ; Mice, Inbred BALB C
References:: Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403–416. https://doi.org/10.1056/NEJMoa2035389. (PMID: 10.1056/NEJMoa2035389)
Dicks MDJ, Spencer AJ, Edwards NJ et al (2012) A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. Plos One 7(7):e40385. https://doi.org/10.1371/journal.pone.0040385. (PMID: 10.1371/journal.pone.0040385228081493396660)
EMA_product_information_Janssen_vaccine (2021) https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf . Accessed 20 July 2021.
EMA_product_information_Vaxzevria (2021) https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf . Accessed 20 July 2021.
Forni G, Mantovani A, Covid-19 Commission of Accademia Nazionale dei Lincei R (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28(2):626–639. https://doi.org/10.1038/s41418-020-00720-9. (PMID: 10.1038/s41418-020-00720-9334793997818063)
Jackson LA, Anderson EJ, Rouphael NG et al (2020) An mRNA vaccine against SARS-CoV-2-preliminary report. N Engl J Med 383(20):1920–1931. https://doi.org/10.1056/NEJMoa2022483. (PMID: 10.1056/NEJMoa202248332663912)
Logunov DY, Dolzhikova IV, Zubkova OV et al (2020) Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 396(10255):887–897. https://doi.org/10.1016/s0140-6736(20)31866-3. (PMID: 10.1016/s0140-6736(20)31866-3328962917471804)
Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577. (PMID: 10.1056/NEJMoa203457733301246)
Tatsis N, Tesema L, Robinson ER et al (2006) Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13(5):421–429. https://doi.org/10.1038/sj.gt.3302675. (PMID: 10.1038/sj.gt.330267516319951)
Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111. https://doi.org/10.1016/s0140-6736(20)32661-1. (PMID: 10.1016/s0140-6736(20)32661-1333069897723445)
Substance Nomenclature:: 0 (COVID-19 Vaccines)
Entry Date(s):: Date Created: 20210806 Date Completed: 20210830 Latest Revision: 20210924
Update Code:: 20240105
PubMed Central ID:: PMC8342650
DOI:: 10.1007/s00204-021-03126-9
PMID:: 34357440
: Opinia redakcyjna

Full Text Finder

Informacja